Keywords: UK, NICE, Pierre Fabre, Javlor, Roche, Tarceva, NSCLC, Bladder cancer

More negative opinions on cancer drugs from UK’s NICE

Article | 11 March 2011

Print This

In two guidance documents issued this week, the UK’s drug watchdog the Institute for Health and Clinical Excellence ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in